- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06426836
Дозирование антибиотиков у детей при экстракорпоральной мембранной оксигенации (PADECMO) (PADECMO)
Дозирование антибиотиков у детей при экстракорпоральной мембранной оксигенации
Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).
Обзор исследования
Статус
Условия
Подробное описание
The study will investigate whether - with the current dosing regimens of meropenem, piperacillin-tazobactam, amoxicillin-clavulanate, cephazolin, vancomycin, amikacin, teicoplanin and ciprofloxacin - pharmacodynamic targets are attained in a national multicentric clinical setting in pediatric patients on ECMO.
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Pieter De Cock, PharmD
- Номер телефона: +32 9 332 29 69
- Электронная почта: pieter.decock@uzgent.be
Места учебы
-
-
-
Ghent, Бельгия, 9000
- Рекрутинг
- University Hospital
-
Контакт:
- Pieter De Cock
- Электронная почта: pieter.decock@uzgent.be
-
Leuven, Бельгия, 3000
- Рекрутинг
- Universitair hospital
-
Контакт:
- Debaveye Yves
- Электронная почта: yves.debaveye@uzleuven.be
-
-
Brussels Capital
-
Brussels, Brussels Capital, Бельгия, 1020
- Рекрутинг
- Queen Fabiola Children's University Hospital
-
Контакт:
- Biarent Dominique
- Электронная почта: dominique.biarent@huderf.be
-
Контакт:
- Vens Daphne
- Электронная почта: daphnevania.vens@huderf.be
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- patients admitted to the pediatric intensive care unit or cardiac intensive care unit
- patient age : 1,8 kg-15 years
- patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin)
- intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)
- extracorporeal membrane oxygenation circuit
Exclusion Criteria:
- no catheter in place for blood sampling
- absence of parental/patient consent
- known hypersensitivity to beta-lactam antibiotics and ciprofloxacin
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Другой
- Распределение: Нерандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Другой: Amoxicillin-clavulanate
Patients receiving amoxicillin-clavulanate as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care
Другие имена:
|
|
Другой: Piperacillin-tazobactam
Patients receiving piperacillin-tazobactam as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care.
Другие имена:
|
|
Другой: Meropenem
Patients receiving meropenem as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving meropenem as part of routine clinical care.
Другие имена:
|
|
Другой: Cefazolin
Patients receiving cefazolin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving cefazolin as part of routine clinical care.
Другие имена:
|
|
Другой: Vancomycin
Patients receiving vancomycin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving vancomycin as part of routine clinical care.
Другие имена:
|
|
Другой: Teicoplanin
Patients receiving teicoplanin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving teicoplanin as part of routine clinical care.
Другие имена:
|
|
Другой: Ciprofloxacin
Patients receiving ciprofloxacin as part of routine clinical care. Study procedure: blood sampling |
blood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care.
Другие имена:
|
|
Другой: Amikacin
Patients receiving amikacin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving amikacin as part of routine clinical care.
Другие имена:
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Amoxicillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Временное ограничение: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Временное ограничение: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Временное ограничение: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Временное ограничение: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amoxicillin, piperacillin, meropenem, cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Временное ограничение: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Временное ограничение: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Временное ограничение: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
Временное ограничение: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
Временное ограничение: up to 1 month
|
% of patients for whom a fAUC/MIC target>86 is achieved with the current dosing regimen off extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
Временное ограничение: up to 1 month
|
% of patients in whom a AUC/MIC target 400-600 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
Временное ограничение: up to 1 month
|
% of patients in whom a trough concentration between 20 to 30 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
for teicoplanin: probability of target attainment with the target being an Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration Ratio (AUC/MIC)
Временное ограничение: up to 1 month
|
% of patients in whom an AUC/MIC of 900 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
for amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
Временное ограничение: up to 1 month
|
% of patients in whom a target peak/MIC ratio of 8 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Временное ограничение: up to 1 month
|
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Временное ограничение: up to 1 month
|
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
Временное ограничение: July 2026
|
% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
July 2026
|
|
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
Временное ограничение: July 2026
|
% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions |
July 2026
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Risk factors for underdosing during extracorporeal membrane oxygenation for beta-lactam antibiotics
Временное ограничение: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a percentage of time during which the unbound concentration remains above the Minimal Inhibitory Concentration (MIC) of the micro-organism of at least 50% and a maximum concentration of 10 x MIC |
up to 1 month
|
|
Risk factors for underdosing during extracorporeal membrane oxygenation for ciprofloxacin
Временное ограничение: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of ciprofloxacin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a free Area-under the concentration-Time Curve of 86 |
up to 1 month
|
|
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for vancomycin
Временное ограничение: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of vancomycin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a free Area-under the concentration-Time Curve of 200 to 300 |
up to 1 month
|
|
Risk factors for underdosing during extracorporeal membrane oxygenation for teicoplanin
Временное ограничение: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of teicoplanin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is an Area-under the concentration-Time Curve of 900 |
up to 1 month
|
|
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for amikacin
Временное ограничение: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of amikacin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a peak over Minimal Inhibitory Concentration Ratio of 8 to 10, trough concentration below 5 mg/L and Area under the Concentration Time Curve/MIC>399 |
up to 1 month
|
|
Beta-lactam antibiotics (amoxicillin, piperacillin, meropenem, cefazolin): probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC)
Временное ограничение: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in first dose conditions |
up to 1 month
|
|
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
Временное ограничение: up to 1 month
|
% of patients for whom a fAUC/MIC target>86 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
Временное ограничение: up to 1 month
|
% of patients in whom a AUC/MIC target 400-600 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
Временное ограничение: up to 1 month
|
% of patients in whom a trough concentration between 20 to 30 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
Временное ограничение: up to 1 month
|
% of patients in whom a target peak/MIC ratio of 8 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
Временное ограничение: up to 1 month
|
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Annick de Jaeger, MD, University Hospital, Ghent
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Пептиды
- Аминокислоты, пептиды и белки
- Средние соединения
- Органические химические вещества
- Гетероциклические соединения
- Гетероциклические соединения, 2-кольцо
- Гетероциклические соединения, слитое кольцо
- Фармацевтические препараты
- Следственные методы
- Обработка образца
- Клинические лабораторные методы
- Диагностические методы и процедуры
- Диагноз
- Проколы
- Хирургические процедуры, оперативные
- Углеводы
- Гликозиды
- Амиды
- Аминогликозиды
- Гликоконъюгаты
- Лекарственные комбинации
- Пенициллин г
- бета-лактамы
- Лактамы
- Клавулановая кислота
- Клавулановые кислоты
- Цефалоспорины
- Тиазины
- Фторхинолоны
- 4 квинолоны
- Хинолоны
- Хинолины
- Сульфоны
- Карбапенемы
- Тиенамицины
- Тазобактам
- Пенициллановая кислота
- Пиперациллин
- Гликопептиды
- Ампициллин
- Пенициллины
- Канамицин
- Липогликопептиды
- Амоксициллин
- Меропенем
- Комбинация препаратов пиперациллин, тазобактам
- Ванкомицин
- Амикацин
- Цефазолин
- Комбинация амоксициллина и клавуланата калия
- Тейкопланин
- Ципрофлоксацин
- Сбор образцов крови
Другие идентификационные номера исследования
- BC-03512 (EC 2015/0529)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .